Inventiva S.A.
Inventiva develops lanifibranor, a pan-PPAR agonist small molecule in Phase 3 trials for metabolic dysfunction-associated steatohepatitis.
8-KNov 12Latest SEC filing
Nov 12Latest story
October 2026
September 2026
August 2026
July 2026
Inventiva develops lanifibranor, a pan-PPAR agonist small molecule in Phase 3 trials for metabolic dysfunction-associated steatohepatitis.
October 2026
September 2026
August 2026
July 2026